TROG 99.02 - Anal Canal - TROG Cancer Research

By w.paterson
14 August, 2021
0 Comments

A Prospective Single Arm Non Randomised Study of Concurrent Radiation and Chemotherapy For the Organ Conserving Treatment of Early Anal Canal Cancer

Primary Sponsor

28 March, 2025

TROG Awards Recognise Research Excellence

Latest news: 28 March 2025. TROG Members who have

27 March, 2025

TROG 2025 ASM advances inclusivity and innovation

Latest news: 27 March 2025 With a theme of

For over 30 years, Trans-Tasman Radiation Oncology Group has been dedicated to improving the way radiation medicine is delivered to cancer patients with ongoing scientific research, clinical trials, and cutting-edge technology.

Quick Links

Legalities

A Prospective Single Arm Non Randomised Study of Concurrent Radiation and Chemotherapy For the Organ Conserving Treatment of Early Anal Canal Cancer

TROG 99.04/ALLG LY02 – Osteolymphoma – OL

ANZLG HD3/TROG 99.01 – Hodgkins Disease IFRT – HD3

Related Post

TROG Awards Recognise Research Excellence

TROG 2025 ASM advances inclusivity and innovation

TROG 99.02 – Anal Canal

A Prospective Single Arm Non Randomised Study of Concurrent Radiation and Chemotherapy For the Organ Conserving Treatment of Early Anal Canal Cancer

TROG 99.04/ALLG LY02 – Osteolymphoma – OL

ANZLG HD3/TROG 99.01 – Hodgkins Disease IFRT – HD3

Related Post

TROG Awards Recognise Research Excellence

TROG 2025 ASM advances inclusivity and innovation